GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Endologix Inc (ELGX) [hlAlert]

Rating:
Overweight
ELGX
down 3.57 %

Endologix Inc (ELGX) upgraded to Overweight by Piper Jaffray

Posted on: Thursday,  Aug 9, 2012  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Endologix Inc (NASDAQ: ELGX) on 08/09/2012, when the stock price was $13.44. Since
then, Endologix Inc has lost 3.57% as of 01/14/2016's recent price of $12.96.
If you would have followed this Piper Jaffray's recommendation on ELGX, you would have lost 3.57% of your investment in 1253 days.

Endologix, Inc., incorporated in March 1992, develops, manufactures, markets and sells treatments for aortic disorders. The Company?s product, the Powerlink System is a minimally invasive device for the treatment of abdominal aortic aneurysm (AAA). AAA is a weakening of the wall of the aorta, an artery of the body. Once AAA develops, it continues to enlarge and if left untreated becomes susceptible to rupture. The Powerlink System is a catheter and endoluminal stent graft (ELG) system. The device consists of a self-expanding cobalt chromium alloy stent cage covered by expanded polytetrafluoroethylene (ePTFE), a surgical graft material. Sale of its Powerlink System in the United States, Europe, Japan and Latin America are the primary sources of the Company?s revenues.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/9/2012 8:25 AM Buy
None
13.44
as of 12/31/2012
1 Week up  5.87 %
1 Month down  -2.86 %
3 Months up  3.03 %
1 YTD up  5.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/10/2009 9:25 AM Hold
None
4.79

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy